MyFinsight
Home
Blog
About
Net income
$67,703K
(-45.51%↓ Y/Y)
Increase in accounts
receivable
-$26,183K
(-294.44%↓ Y/Y)
Depreciation and
amortization
$16,986K
(-47.37%↓ Y/Y)
Stock option expense
$9,053K
(-50.55%↓ Y/Y)
Increase/(decrease) in accounts
payable and other...
$6,939K
(155.74%↑ Y/Y)
Increase in other
liabilities
$4,482K
(194.67%↑ Y/Y)
Noncash long-term
incentive compensation
$2,247K
(-31.35%↓ Y/Y)
Noncash directors'
compensation
$1,191K
(6.06%↑ Y/Y)
Net change in lease
assets and liabilities
-$763K
(-1159.72%↓ Y/Y)
Litigation settlements
$548K
Benefit for deferred
income taxes
$475K
(103.59%↑ Y/Y)
Other sources
$467K
(140.72%↑ Y/Y)
Amortization of debt issuance
costs
$83K
(-48.13%↓ Y/Y)
Net cash provided by
operating activities
$84,813K
(-50.50%↓ Y/Y)
Canceled cashflow
$52,307K
(decrease)/increase in cash and cash
equivalents
$23,366K
(-67.34%↓ Y/Y)
Canceled cashflow
$61,447K
Change in current
income taxes
-$35,802K
(-232.61%↓ Y/Y)
Increase in prepaid
expenses
$10,197K
(41.00%↑ Y/Y)
(increase)/decrease in other assets
$5,886K
(112.15%↑ Y/Y)
Increase in inventories
$422K
(-55.81%↓ Y/Y)
Proceeds from revolving
line of credit
$356,000K
Change in cash
overdrafts payable
$23,798K
(7601.62%↑ Y/Y)
Proceeds from exercise of
stock options
$1,419K
(-94.77%↓ Y/Y)
Proceeds from sale of
fixed assets
$288K
(-40.00%↓ Y/Y)
Net cash used by
financing activities
-$33,209K
(52.99%↑ Y/Y)
Net cash used by
investing activities
-$28,238K
(3.15%↑ Y/Y)
Canceled cashflow
$381,217K
Canceled cashflow
$288K
Payments on revolving
line of credit
$307,200K
Capital expenditures
$15,523K
(-46.63%↓ Y/Y)
Business combinations,
net of cash acquired
$12,930K
(5646.67%↑ Y/Y)
Purchases of treasury
stock
$97,482K
(27.98%↑ Y/Y)
Dividends paid
$7,876K
(-45.84%↓ Y/Y)
Debt issuance costs
$1,349K
Other (uses)/sources
-$519K
(-147.53%↓ Y/Y)
Other uses
$73K
(-77.33%↓ Y/Y)
Back
Back
Cash Flow
CHEMED CORP (CHE)
CHEMED CORP (CHE)
source: myfinsight.com